Skip to content
Clinical Trials – home
RomaniaBack to Romania

Clinical trials in Otopeni – page 12

679 clinical trials in Otopeni, Romania. Every trial is listed in the EU Clinical Trials Register and updated daily.

RomaniaOur site in RomaniaStudii.Clinice.ro(opens in a new tab)
Otopeni at a glance
679
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

679 trials in Otopeni

Open in trial search

A study of pumitamig and a drug combination versus bevacizumab and a drug combination for patients with untreated, unresectable, or metastatic colorectal cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

A study of the humanised IgG1 lalaps-yte monoclonal antibody against lysophosphatidic acid receptor 1 to treat adults with idiopathic pulmonary fibrosis

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:ABBV-142
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Orforglipron hemicalcium
  • Sponsor:Eli Lilly & Co.

Short stature+1

Recruiting

Study of Lonapegsomatrin and Somatropin in Children and Adolescents with Short Stature or Growth Failure due to Turner Syndrome, SHOX Deficiency, SGA, or Idiopathic Short Stature

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:0–17 years
  • Substances:Lonapegsomatropin
  • Sponsor:Ascendis Pharma Endocrinology Division A/S

A study of palazestrant and ribociclib compared to letrozole and ribociclib for patients with advanced ER+ HER2- breast cancer

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Letrozole
  • Sponsor:Olema Pharmaceuticals Inc.

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:LY3437943 sodium
  • Sponsor:Eli Lilly & Co.

Evaluation of Lymphocyte-Sparing Radiotherapy and All-Trans Retinoic Acid in Lateralized Oropharyngeal, Laryngeal, and Hypopharyngeal Squamous Cell Carcinoma

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Centre Leon Berard

Evaluation of Long-Term Safety and Efficacy of Litifilimab in Adults with Active Systemic Lupus Erythematosus: A Phase 3 Multicenter, Randomized, Dose-Blind Study

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Litifilimab
  • Sponsor:Biogen Idec Research Limited

Study of GSK6042981 compared to sunitinib for patients with gastrointestinal stromal tumors that spread or cannot be removed after imatinib treatment

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Sunitinib
  • Sponsor:Glaxosmithkline Research & Development Limited

Hepatitis D

Recruiting

A study comparing brelovitug to bulevirtide for treating chronic hepatitis delta infection in patients currently receiving bulevirtide

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:BJT-778
  • Sponsor:Mirum Pharmaceuticals Inc.

Hepatitis D+1

Recruiting

Study of GS-4321 for Healthy People and Patients With Chronic Hepatitis Delta Virus Infection

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:GS-4321
  • Sponsor:Gilead Sciences Inc.

Testing MK-2870 with pembrolizumab compared to pembrolizumab alone after surgery in patients with non-small cell lung cancer who did not respond fully to treatment

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Romania

The busiest research cities in the country

All 63 cities in Romania

Clinical research in Otopeni

What the registry says about research in the country

01 Lung Cancer Research

Investigating innovative treatments for non-squamous non-small cell lung cancer (NSCLC), with a focus on patients exhibiting specific genetic markers like c-Met overexpression. Studies are evaluating the effectiveness of targeted therapies compared to standard treatments.

  • EGFR wildtype NSCLC
  • Treatment resistance patterns
  • Targeted therapy approaches

Research aims to improve survival rates and treatment outcomes for lung cancer patients.

02 Urological Oncology

Comprehensive studies focusing on renal cell carcinoma and high-risk prostate cancer. Clinical trials are exploring combination therapies and novel treatment approaches including hormone therapy with radiation treatment.

  • Advanced kidney cancer treatments
  • Prostate cancer management
  • Combination therapy efficacy

Research centers on improving disease-free survival and treatment outcomes.

03 Skin Cancer Studies

Groundbreaking research in advanced melanoma treatment, investigating the potential of combination immunotherapy approaches. Studies are comparing various therapeutic combinations to establish optimal treatment protocols.

  • Immunotherapy combinations
  • Advanced melanoma management
  • Treatment effectiveness markers

Focus on developing more effective first-line treatments for unresectable melanoma.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.